Page 31 - ASPRI2223 eDirectory
P. 31

 BioNTech’s revenue rose 3,835% to €19 billion while net profit increased by an astounding 67,614% to €10.3 billion. Following its success, the company has raised its R&D spend for 2022 to €1.4 billion - €1.5 billion, about 50% more than 2021.
“To continue our industry leadership, we intend to build on our 2021 success and rapidly advance multiple programmes, including our mRNA-based immunotherapies, cell therapies, and bi-specific antibodies. At the same time, we are investing in our second growth pillar, infectious diseases, and intend to advance our influenza and shingles vaccine candidates together with our partner Pfizer. In parallel, we also intend to invest heavily in regenerative medicine and autoimmune diseases with the aim to develop further therapeutic innovations addressing high unmet medical need. Our core vision remains the foundation for all our activities: harnessing the power of the immune system to improve the health and lives of billions of people worldwide,” said Mr Ugur Sahin, M.D., CEO and Co-Founder of BioNTech.
For Moderna, its Covid-19 vaccine, Spikevax, was a giant shot in the arm for the
company lifting its revenue 2,200% to US$18.5 billion in 2021. Spikevax, the company’s only commercially available product, accounted for US$17.7 billion of 2021 sales. Net profits rose to US$12.2 billion in 2021 from a net loss of US$747 million in 2020.
Moderna CEO Stéphane Bancel said, “Spikevax is now approved in more than 70 countries around the world protecting hundreds of millions of people and real-world evidence from multiple independent studies has confirmed its strong effectiveness.”
“In 2021, we delivered 807 million doses with approximately 25% of those doses going to low- and middle-income countries, and we will continue to scale in 2022 to help end the Covid-19 pandemic.”
annual growth rate (CAGR) of 3-6% to reach US$1.8 trillion in 2026. The cumulative global spending on vaccines and therapeutics will account for a sizeable chunk of the total.
IQVIA noted, “The total cumulative spending on Covid-19 vaccines since their introduction through 2026 is projected to be US$251 billion, largely from the initial wave of vaccinations to be completed by 2022 in most countries. In subsequent years, booster shots are expected to be required annually or more often as the limited durability of immunity and the continued emergence of viral variants drive recommendations for additional inoculations.”
IQVIA expects another
US$58 billion will be spent
on therapeutics
With such massive sums channelled towards addressing the ill effects of Covid, non-Covid spending on medicines is expected to drop by US$175 billion over the same period. IQVIA estimates the net increase in global spending on medicine over the next five years to be US$133 billion.
Pharmerging markets led by China will drive spending growth over the forecast period rising by 2.5% to 5.5%. US, the world’s biggest market, is forecast to grow at 0 to 3% CAGR over the next five years, down from 3.5% CAGR in the previous five years, while Japan, the third biggest market, will have flat-to-declining medicine spending.
IQVIA expects 300 drugs to be launched during the period, significantly higher than levels seen during the past decade, skewed toward specialty, niche and orphan drugs. The two leading global therapy areas - oncology and
Steady increase in global
spend on medicines
Driven by Covid-19 vaccinations, global spending on medicines is expected to trend up. TheIQVIAInstituteforHumanDataScience projects that it will increase at a compound

   29   30   31   32   33